Market capitalization | $8.59b |
Enterprise Value | $3.68b |
P/E (TTM) P/E ratio | 2.09 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 29.28 |
P/S ratio (TTM) P/S ratio | 68.35 |
P/B ratio (TTM) P/B ratio | 1.68 |
Revenue growth (TTM) Revenue growth | 21.84% |
Revenue (TTM) Revenue | $125.68m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
10 Analysts have issued a Roivant Sciences forecast:
10 Analysts have issued a Roivant Sciences forecast:
Sep '24 |
+/-
%
|
||
Revenue | 126 126 |
22%
22%
|
|
Gross Profit | 121 121 |
77%
77%
|
|
EBITDA | -1,115 -1,115 |
10%
10%
|
EBIT (Operating Income) EBIT | -1,126 -1,126 |
8%
8%
|
Net Profit | 4,810 4,810 |
590%
590%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Head office | Bermuda |
CEO | Matthew Gline |
Employees | 908 |
Founded | 2014 |
Website | www.roivant.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.